EGFR mutation testing from pleural effusions of non-small cell lung cancer patients at the institute for oncology and radiology of Serbia

[1]  Chun-Ta Huang,et al.  Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors , 2023, BMC Cancer.

[2]  F. Eduati,et al.  Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer , 2022, Translational oncology.

[3]  M. Rowbotham,et al.  Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience , 2022, Journal of personalized medicine.

[4]  K. To,et al.  EGFR testing in paraffin-embedded cell block cytology material is reliable with increased detection for effusion fluid. , 2022, Lung cancer.

[5]  R. Janković,et al.  Lung Cancer in Serbia. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  D. Radosavljevic,et al.  Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung Adenocarcinoma , 2022, Dose-response : a publication of International Hormesis Society.

[7]  C. Pericone,et al.  Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations , 2022, Advances in Therapy.

[8]  J. Spasić,et al.  Special Collection:-Inflammatory Parameters as Early Biomarkers in Prediction and Monitoring of Therapeutic Effects in Preclinical and Clinical Studies , 2022 .

[9]  P. Jänne,et al.  ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  C. Chiu,et al.  Cytology–Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Non–Small Cell Lung Cancer , 2022, Frontiers in Oncology.

[11]  Nóra Bittner,et al.  Malignant pleural effusions for cancer genotyping: A matter of trans-pleural traffic of cell-free tumor DNA. , 2022, Molecular and cellular probes.

[12]  S. Bielsa,et al.  Cell-free DNA Concentration and Pattern Fragmentation in Pleural Fluid and Plasma to Detect Malignant Effusions. , 2021, Annals of the American Thoracic Society.

[13]  E. Kazerooni,et al.  Screening for lung cancer in individuals who never smoked: An IASLC Early Detection and Screening Committee Report. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  L. Brunsveld,et al.  Sensitive cell-free tumor DNA analysis in supernatant pleural effusions supports therapy selection and disease monitoring of lung cancer patients. , 2021, Cancer treatment and research communications.

[15]  H. Grosu,et al.  Cytologic Investigations for the Diagnosis of Malignant Pleural Effusion in Non–small Cell Lung Cancer , 2021, Journal of bronchology & interventional pulmonology.

[16]  Nóra Bittner,et al.  Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma? , 2021, Pathology & Oncology Research.

[17]  J. Spasić,et al.  Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity , 2021, Expert review of anticancer therapy.

[18]  Shun Lu,et al.  Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing , 2021, International journal of medical sciences.

[19]  D. Radosavljevic,et al.  Exploring the real-world effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals , 2020, Expert review of molecular diagnostics.

[20]  L. Crinò,et al.  Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR , 2020, Diagnostics.

[21]  R. Guo,et al.  A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer , 2020, Translational lung cancer research.

[22]  M. Catalán,et al.  Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions , 2019, Molecular oncology.

[23]  X. Nie,et al.  Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma , 2019, Thoracic cancer.

[24]  K. Takayama,et al.  Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis , 2019, Thoracic cancer.

[25]  A. Krivokuca,et al.  TP53 and DNA-repair gene polymorphisms genotyping as a low-cost lung adenocarcinoma screening tool , 2018, Journal of Clinical Pathology.

[26]  K. Kristiansen,et al.  Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens. , 2018, Journal of thoracic disease.

[27]  D. Lin,et al.  A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients , 2018, Cancer management and research.

[28]  B. Han,et al.  EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. , 2017, Lung cancer.

[29]  Yoonjung Kim,et al.  Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients , 2017, Clinical chemistry and laboratory medicine.

[30]  S. Beck,et al.  Cell-free DNA: Treasure trove for cancer medicine. , 2017, Nature materials.

[31]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[32]  S. Radulović,et al.  Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia. , 2016, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[33]  C. Michael,et al.  Pre-analytical issues in effusion cytology , 2016, Pleura and peritoneum.

[34]  T. Agalioti,et al.  Pleural involvement in lung cancer. , 2015, Journal of thoracic disease.

[35]  J. M. Porcel,et al.  Clinical features and survival of lung cancer patients with pleural effusions , 2015, Respirology.

[36]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[37]  D. Radosavljevic,et al.  The influence of methylenetetrahydrofolate reductase and thymidylate synthetase gene polymorphisms on lung adenocarcinoma occurrence. , 2014, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[38]  C. Liam,et al.  EGFR mutations in Asian patients with advanced lung adenocarcinoma. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[40]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.

[41]  M. Froudarakis.  Pleural Effusion in Lung Cancer: More Questions than Answers , 2012, Respiration.

[42]  Clare Hooper,et al.  Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[43]  A. Damjanović,et al.  EGFR mutation testing from liquid biopsy of non-small cell lung cancer at the Institute for Oncology and Radiology of Serbia. , 2020, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[44]  R. Janković,et al.  Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid. , 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[45]  R. Janković,et al.  LungCARD - Report on worldwide research and clinical practices related to lung cancer. , 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.